| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/03/2005 | WO2005009397A2 Human lymphocyte vaccine adjuvant |
| 02/03/2005 | WO2005009396A2 Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
| 02/03/2005 | WO2005009379A2 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 02/03/2005 | WO2005009378A2 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 02/03/2005 | WO2005009372A2 Marek’s disease virus vaccine |
| 02/03/2005 | WO2005009369A2 A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 02/03/2005 | WO2005009366A2 Restoring vascular function |
| 02/03/2005 | WO2005009363A2 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies |
| 02/03/2005 | WO2005009335A2 Live attenuated nidovirus vaccines |
| 02/03/2005 | WO2005009225A2 Tissue adhesive sealant |
| 02/03/2005 | WO2005009217A2 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 02/03/2005 | WO2004112835A3 Suppression of transplant rejection |
| 02/03/2005 | WO2004106366A8 Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
| 02/03/2005 | WO2004087202A3 Pharmaceutical composition comprising a macrolide immunomodulator |
| 02/03/2005 | WO2004081190A3 Uses of il-23 agonists and antagonists; related reagents |
| 02/03/2005 | WO2004076639A3 Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
| 02/03/2005 | WO2004050855A3 Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
| 02/03/2005 | WO2004048431A3 Polyphosphazene immunocstimulants |
| 02/03/2005 | WO2004045641A3 Antigen-complexes |
| 02/03/2005 | WO2004045550A3 Immunization with porphyromonas gingivalis protects against heart disease |
| 02/03/2005 | WO2004000351A8 Packaged virus-like particles for use as adjuvants: method of preparation and use |
| 02/03/2005 | WO2003094859A3 Epha2 monoclonal antibodies and methods of use thereof |
| 02/03/2005 | WO2003070890A3 THE p65 SUBUNIT OF NF-κB FOR THE RADIOSENSITIZATION OF CELLS |
| 02/03/2005 | WO2003064606A3 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2003040317A8 Lung cancer therapeutics and diagnostics |
| 02/03/2005 | WO2003039342A3 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 |
| 02/03/2005 | WO2003037248A3 Fibrin nanoparticles and uses thereof |
| 02/03/2005 | US20050027115 Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| 02/03/2005 | US20050027109 Preparing genetically engineered therapeutic protein fusion comprised of antibody constant region for use in treatment of metabolic disorders |
| 02/03/2005 | US20050027104 Antibodies for use in diagnosis, prevention and treatment of autoimmune disease |
| 02/03/2005 | US20050027103 Matrix protein for use diagnosis, treatment, and prevention of viral infections, cell proliferative and neurological disorders |
| 02/03/2005 | US20050026881 Immunoglobulin E (IgE); antibody such as omalizumab; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026858 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups |
| 02/03/2005 | US20050026856 A biological drug conjugates for binding human lupus anti-dsDNA autoantibodies; antibody inhibitor; conjugated with carbohydrates, drugs, lipids, lipopolysaccharides, peptides, proteins, glycoproteins, single-stranded or double-stranded oligonucleotides, haptens |
| 02/03/2005 | US20050026831 inhibitors of notch signalling comprising proteins or polypeptides having notch ligand domains, multimeric proteins or polynucleotide codes for the protein or polypeptides, used in the treatment of cancer; vaccines |
| 02/03/2005 | US20050026823 Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| 02/03/2005 | US20050026283 Using electric field modification to transfer components across cell barriers; organelle transfer; in vitro fertility |
| 02/03/2005 | US20050026271 subunit vaccines for dental caries; rather than using intact GTF as an immunizing agent, the vaccine is prepared from particular immunogenic portions (subunits) of GTF |
| 02/03/2005 | US20050026257 Injecting Dna containing virus codes into mammal; testing serum for antibodies ; cloning genes |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026232 Monoclonal antibody which preferentially binds leukocyte common antigen-related molecule phosphatase (LAR) for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 02/03/2005 | US20050026229 Cell line for use in generating monoclonal antibodies specific for prostate stem cell antigen (PSCA) for use in diagnosis of cell proliferative disorders; immunodiagnostics |
| 02/03/2005 | US20050026220 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/03/2005 | US20050026215 Method for the prediction of an epitope |
| 02/03/2005 | US20050026211 Compositions and methods relating to lung specific genes |
| 02/03/2005 | US20050026170 Extracellular matrix-binding proteins from Staphylococcus aureus |
| 02/03/2005 | US20050025790 Endogenous adjuvant molecules and uses thereof |
| 02/03/2005 | US20050025789 Administering to a patient exhibiting no congruence in their major histocompatibility (MHC) molecules; activation of lytic activity of natural killer (NK) cells; anticarcinogenic agents |
| 02/03/2005 | US20050025787 Transformed bacteria producing CS6 antigens as vaccines |
| 02/03/2005 | US20050025784 Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
| 02/03/2005 | US20050025783 Vaccine |
| 02/03/2005 | US20050025782 Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| 02/03/2005 | US20050025781 Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| 02/03/2005 | US20050025780 Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations |
| 02/03/2005 | US20050025779 Immunogenic gp120 polypeptides and polynucleotides; expression vectors and host cells; medical diagnosis; vaccines |
| 02/03/2005 | US20050025777 Particle-mediated delivery of antigens |
| 02/03/2005 | US20050025775 Contacting a sample with an isolated monoclonal antibody that binds to a substantially-pure coagulase-negative Staphylococcus epidermidis capsular polyssocharide adhesin antigen that binds to polymeric material, wherein said adhesin antigen inhibits binding to polymeric material |
| 02/03/2005 | US20050025774 Such as N-(2-ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; for preventing, treating or delaying AIDS |
| 02/03/2005 | US20050025771 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 02/03/2005 | US20050025770 Immunological methods for the treatment of gastrointestinal cancer |
| 02/03/2005 | US20050025769 Method of suppressing ongoing acute allograft rejection |
| 02/03/2005 | US20050025763 Therapeutic use of anti-CS1 antibodies |
| 02/03/2005 | US20050025761 immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | US20050025747 Containing a priming and boosting composition, each with a non-replicating viral vector, with at least one of them being derived from a fowlpox virus; malaria, tuberculosis |
| 02/03/2005 | US20050025744 Administration of humanized anti-IP-10 antibody in combination with beta-interferon 1a, beta-interferon 1b, glatiramer acetate, or humanized anti-VLA-4-antibody |
| 02/03/2005 | US20050025717 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 02/03/2005 | US20050025716 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 02/03/2005 | US20050025715 Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
| 02/03/2005 | US20050025714 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 02/03/2005 | US20050025713 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 02/03/2005 | US20050025712 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant |
| 02/03/2005 | DE10329087A1 Antigenhaltige Mikrosphären zur Allergietherapie Antigen-containing microspheres for allergy therapy |
| 02/03/2005 | CA2536644A1 Antibodies and uses thereof |
| 02/03/2005 | CA2533551A1 Tissue adhesive sealant |
| 02/03/2005 | CA2533503A1 Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections |
| 02/03/2005 | CA2533113A1 Soluble fragments of the sars-cov spike glycoprotein |
| 02/03/2005 | CA2532582A1 Keratinocyte culturing method and the use thereof |
| 02/03/2005 | CA2532547A1 Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
| 02/03/2005 | CA2532430A1 Humanized versions of monoclonal antibody ds6 that bind tumour antigen ca6 |
| 02/03/2005 | CA2532394A1 Rg1 antibodies and uses thereof |
| 02/03/2005 | CA2532370A1 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 02/03/2005 | CA2532250A1 Compositions and methods for immunotherapy of cancer and infectious diseases |
| 02/03/2005 | CA2532035A1 Fugetactic proteins, compositions and methods of use |
| 02/03/2005 | CA2531073A1 Human mast cell-expressed membrane protein |
| 02/03/2005 | CA2530285A1 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/03/2005 | CA2530284A1 Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| 02/03/2005 | CA2528440A1 Replikin peptides and uses thereof |
| 02/03/2005 | CA2528043A1 Marks as modifiers of the pten pathway and methods of use |
| 02/03/2005 | CA2526240A1 7a5/prognostin and use thereof for the diagnostic and therapy of tumors |
| 02/03/2005 | CA2517600A1 Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
| 02/03/2005 | CA2516783A1 Human lymphocyte vaccine adjuvant |
| 02/02/2005 | EP1502920A2 Cell surface molecule mediating cell adhesion and signal transmission |
| 02/02/2005 | EP1502603A1 DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM |
| 02/02/2005 | EP1502602A2 Methods for therapeutic vaccination |
| 02/02/2005 | EP1502599A1 Active antiangiogenic therapy |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501921A1 Improved viral purification methods |
| 02/02/2005 | EP1501870A2 Rsv proteins, antibodies, compositions, methods and uses |